Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present six oral and three poster presentations at the 65th American Society of Hematology (ASH) Meeting & Exposition, occurring in San Diego, California and virtually December 9 - 12, 2023. The presentations focus on treatments for acute leukemias and lymphoma.
Among the data are the promising results of the phase 2 PrE0405 trial, which evaluated bendamustine, rituximab, and venetoclax for the initial treatment of mantle cell lymphoma in older patients. Other abstracts are secondary analyses from the practice-changing E1910 phase 3 trial (Abstract LBA-1 at ASH 2022).
Details for the nine presentations are below, listed by type and date.